Use of the 22C3 anti–PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms

BACKGROUND: For non–small cell lung cancer (NSCLC), treatment with pembrolizumab is limited to patients with tumours expressing PD-L1 assessed by immunohistochemistry (IHC) using the PD-L1 IHC 22C3 pharmDx (Dako, Inc.) companion diagnostic test, on the Dako Autostainer Link 48 (ASL48) platform. Opti...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:PLoS One
Autori principali: Ilie, Marius, Khambata-Ford, Shirin, Copie-Bergman, Christiane, Huang, Lingkang, Juco, Jonathan, Hofman, Veronique, Hofman, Paul
Natura: Artigo
Lingua:Inglês
Pubblicazione: Public Library of Science 2017
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5552229/
https://ncbi.nlm.nih.gov/pubmed/28797130
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0183023
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi